Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University of Mississippi Medical Center
With
Novartis
Omalizumab is an FDA approved anti-IgE drug used to treat allergic asthma. This study is designed to give omalizumab 13 weeks prior to administering rapid build up of specific allergy shot, with an overlap of omalizumab and cluster therapy for 3 weeks. The cluster therapy will take 4 week to complete with maintenance dosage lasting an additional 6 weeks.
Age
18–55
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
clinical diagnosis and history of moderate persistent allergic asthma
body weight \>/= 20kg and \</= 150kg
Total serum IgE \>/= 30 and \</= 700IU/mL
on a stable asthma treatment including corticosteroids for the preceding 4 weeks
non smoker for at least 1 year prior to visit 1
You may not be if
patients with severe asthma
history of immunotherapy to any allergen within the past 3 years
